Doxil Wins Full Approval for Relapsed Ovarian Ca
FDA’s phase III study proves Doxil’s benefit in relapsed ovarian cancer, leading to full approval.
The FDA’s phase III trial demonstrates Doxil’s clinical benefit in patients with relapsed ovarian cancer, showing comparable progression‑free survival to topotecan, and thus earns full regulatory approval for this indication.
The approval of Doxil expands treatment options for women whose ovarian cancer has recurred after platinum‑based chemotherapy, offering an evidence‑based alternative with similar efficacy to existing regimens.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements